REMARKS

Restriction/Election

Applicants maintain that it has not been shown to be an undue burden to examine the full scope of the subject matter defined in claim 8. The sample search discussed in the Office Action does not include all of the limitations required of the subject matter defined in claim 8. It appears only a urea group and a pyridyl group were required, whereas the subject matter of claim 8 additionally requires a bridged cyclic structure of the formula (L-M)-L¹, wherein L¹ comprises a 5- to 6-membered aryl moiety or hetaryl moiety and hetaryl moiety comprises 1 to 4 members selected from the group of heteroatoms consisting of nitrogen, oxygen and sulfur. Furthermore, applicants point out that the examination of the corresponding international application did not require such a restriction and it would not be an undue burden to update the search performed for the corresponding international application.

Rejection Under 35 U.S.C. § 112

Applicants maintain that there is adequate written description for the subject matter defined by all claims when considered as a whole. The language objected to pertains to substituents which appear on well-defined urea compounds. One of skilled in the art would recognize that applicants have possession of compounds with such broadly defined substituents based on the preferred values given for R_y , R_z , R_a , R_b , R_g , etc., as well as the numerous examples of these groups given in the specification. The rejection has been directed to claims 1, 2, 6, 37, 38 and 44. The language objected to has been deleted from claims 37 and 44 and so the rejection is moot with respect to these claims.

Scope of Enablement

Applicants maintain claims 1-30 satisfy the requirements of 35 U.S.C. § 112, first paragraph. Both the generic and specific disclosure teach how to make and use the full scope

Appl. No.: 09/777,920

May 21, 2004

Reply to final Office Action of 01/21/2004

Page 31

of compounds defined by formula I herein. The specification provides both general and

specific methods for making compounds consistent with formula I and both dosages and

methods of administering these compounds are given within the specification. The examiner

has not provided any evidence to demonstrate otherwise and therefore, applicants submit that

the subject matter of the claims 1-30 is enabled.

Rejection Under 35 U.S.C. § 112, second paragraph

Applicants have amended claims 39 and 41 and the method of treatment claims such

that this rejection is now moot.

Based on the above remarks, applicants submit that the examination of the subject

matter within claim 8 and the claims which correspond thereto should continue, and that

claims which conform to the elected subject matter, i.e., claims 37-48, are in condition for

allowance.

The Commissioner is hereby authorized to charge any fees associated with this

response or credit any overpayment to Deposit Account No. 13-3402.

Respectfully submitted

Richard J. Traverso, Reg. No. 30,595

Attorney/Agent for Applicants

MILLEN, WHITE, ZELANO & BRANIGAN, P.C.

Arlington Courthouse Plaza 1, Suite 1400

2200 Clarendon Boulevard

Arlington, Virginia 22201

Telephone: (703) 243-6333 Facsimile: (703) 243-6410

Attorney Docket No.:

BAYER-0015-P03

Date:

May 21, 2004

RJT/dm(K:\BAYER\I\$P3\RAFR to 1-21-04 FOA.doe